- Single-center, randomized, double-blind, placebo-controlled pilot trial of 100 critically ill adults with CAM-ICU-confirmed delirium in surgical and trauma ICUs.
- Patients received 2 mg guanfacine or matching placebo nightly for up to 14 days, or until ICU discharge or delirium resolution.
- Median delirium and coma-free days were 2 (IQR 0-6) with guanfacine versus 1 (IQR 0-4) with placebo (p = 0.02) in unadjusted analyses, but not significant after adjustment.
- Feasibility targets were mostly met, with 100% adherence, retention, and data completeness, though COVID-19 limited recruitment to 0.9 patients/week; authors judge the signal worth a multicenter trial.
Neuro
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Single-centre, double-blind randomised noninferiority trial of 686 adults having elective neurovascular surgery, analysed as a modified intention-to-treat population.
- Patients received remimazolam-based TIVA with flumazenil reversal at emergence or propofol-based TIVA, both with remifentanil.
- Postoperative delirium within 5 days occurred in 12.8% (44/344) with remimazolam and 10.8% (37/342) with propofol; risk difference 1.97 percentage points (95% CI -2.85 to 6.80).
- Remimazolam met the prespecified noninferiority criterion, and that group had less intraoperative hypotension below a MAP of 65 mm Hg and more operating-room extubation.